Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

metastatic hormone-sensitive prostate cancer

- PMLiVE

Loxo’s cancer drug pair attracts $1.5bn deal with Bayer

The German pharma group will gain full rights to the drugs outside the US

Orion appoints VP of oncology, R&D

Professor Heikki Joensuu joins from Helsinki University Hospital

- PMLiVE

Bayer appoints senior vice president for consumer health unit

Brenda Raphael joins from Pfizer, where she was general manager

Bayer UK and Ireland appoints new CEO

Lars Bruening succeeds Alex Moscho

- PMLiVE

Bayer picks digital firms for open innovation support

Four new start-ups enter its Grants4Apps Accelerator programme

Bayer picks digital firms for open innovation support

Four new start-ups enter its Grants4Apps Accelerator programme

- PMLiVE

Xarelto no better than aspirin in secondary stroke study

The NOAC has 'very little' chance of showing overall benefit, says data monitoring committee

Bayer appoints new head of global innovation and development, consumer health

Dr Sharon James succeeds Dr John O’Mullane

- PMLiVE

NICE first fast-track appraisal backs Bayer’s Eylea

But company will have to reduce its cost through a patient access scheme

Bayer symbol

Bayer bags speedy US approval for lymphoma drug Aliqopa

FDA decision sets the pharma firm up for a showdown with Gilead's Zydelig

- PMLiVE

Bayer appoints Wolfgang Nickl as chief financial officer

He will succeed Johannes Dietsch on June 1, 2018

Roche Basel Switzerland

UK is first to receive Roche’s rare lung cancer drug

Alecensa made available under MHRA's early access scheme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links